Mabwell Gets Chinese Regulatory Nod to Expand Indication of Denosumab
MT Newswires Live
May 21
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) said Chinese regulators expanded denosumab's approval to include new indications, according to a Wednesday filing with the Hong Kong bourse.
The firm's Hong Kong shares gained nearly 4% in morning trade Thursday.
Denosumab, also known as maiweijian and 9MW0321, will now be available to treat bone metastases from solid tumors and to delay or reduce the risk of skeletal-related events in patients with multiple myeloma.
The medicine, a biosimilar version of Xgeva, was previously approved in China to treat giant cell tumor of the bone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.